UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2012 (June 27, 2012)

NewLink Genetics Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) **001-35342** (Commission File Number) **42-1491350** (IRS Employer Identification No.)

2503 South Loop Drive Ames, IA (Address of principal executive offices)

50010 (Zip Code)

Registrant's telephone number, including area code: (515) 296-5555

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02(b) and (e). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 27, 2012, Kenneth R. Lynn resigned from his position as Executive Vice President of Business Development. However, Mr. Lynn will continue to be an employee of the Company as the Head of Business Development on a part-time basis. Mr Lynn's existing Employment Agreement has been terminated by mutual agreement. As Head of Business Development, Mr. Lynn will receive an annual salary of \$100,000 and other standard employee benefits. His existing stock options will continue to vest in accordance with their terms. He will also receive a one-time payment of \$7,500 representing the reduced value of vacation days carried over.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 27, 2012

NewLink Genetics Corporation

By: <u>/s/ Gordon H. Link, Jr.</u>

Gordon H. Link, Jr.

Its: Chief Financial Officer

3